Abstract
We conducted a multicentre test-negative case–control study in 27 hospitals of 11 European countries to measure 2015/16 influenza vaccine effectiveness (IVE) against hospitalised influenza A(H1N1)pdm09 and B among people aged ≥ 65 years. Patients swabbed within 7 days after onset of symptoms compatible with severe acute respiratory infection were included. Information on demographics, vaccination and underlying conditions was collected. Using logistic regression, we measured IVE adjusted for potential confounders. We included 355 influenza A(H1N1)pdm09 cases, 110 influenza B cases, and 1,274 controls. Adjusted IVE against influenza A(H1N1)pdm09 was 42% (95% confidence interval (CI): 22 to 57). It was 59% (95% CI: 23 to 78), 48% (95% CI: 5 to 71), 43% (95% CI: 8 to 65) and 39% (95% CI: 7 to 60) in patients with diabetes mellitus, cancer, lung and heart disease, respectively. Adjusted IVE against influenza B was 52% (95% CI: 24 to 70). It was 62% (95% CI: 5 to 85), 60% (95% CI: 18 to 80) and 36% (95% CI: -23 to 67) in patients with diabetes mellitus, lung and heart disease, respectively. 2015/16 IVE estimates against hospitalised influenza in elderly people was moderate against influenza A(H1N1)pdm09 and B, including among those with diabetes mellitus, cancer, lung or heart diseases.
| Original language | English |
|---|---|
| Journal | Eurosurveillance |
| Volume | 22 |
| Issue number | 30 |
| DOIs | |
| Publication status | Published - Jul 27 2017 |
Fingerprint
ASJC Scopus subject areas
- Epidemiology
- Public Health, Environmental and Occupational Health
- Virology
Cite this
2015/16 seasonal vaccine effectiveness against hospitalisation with influenza a(H1N1)pdm09 and B among elderly people in Europe : Results from the I-MOVE+ project. / I-MOVE+ hospital working group.
In: Eurosurveillance, Vol. 22, No. 30, 27.07.2017.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - 2015/16 seasonal vaccine effectiveness against hospitalisation with influenza a(H1N1)pdm09 and B among elderly people in Europe
T2 - Results from the I-MOVE+ project
AU - I-MOVE+ hospital working group
AU - Rondy, Marc
AU - Larrauri, A.
AU - Casado, I.
AU - Alfonsi, V.
AU - Pitigoi, D.
AU - Launay, O.
AU - Syrjänen, R. K.
AU - Gefenaite, G.
AU - Machado, A.
AU - Vučina, V. V.
AU - Horváth, J. K.
AU - Paradowska-Stankiewicz, I.
AU - Marbus, S. D.
AU - Gherasim, A.
AU - Díaz-González, J. A.
AU - Rizzo, C.
AU - Ivanciuc, A. E.
AU - Galtier, F.
AU - Ikonen, N.
AU - Mickiene, A.
AU - Gomez, V.
AU - Kurečić Filipović, S.
AU - Ferenczi, A.
AU - Korcinska, M. R.
AU - Van Gageldonk-Lafeber, R.
AU - Valenciano, M.
AU - Altzibar, Jone M.
AU - Arraras, Ion Garcia
AU - Cilla, Gustavo
AU - Marco, Elisa
AU - Vidal, Matxalen
AU - Omenaca, Manuel
AU - Castilla, J.
AU - Navascues, A.
AU - Ezpeleta, C.
AU - Barrado, L.
AU - Ortega, M. T.
AU - Bella, A.
AU - Castrucci, M. R.
AU - Puzelli, S.
AU - Chironna, M.
AU - Germinario, C.
AU - Ansaldi, F.
AU - Orsi, A.
AU - Manini, I.
AU - Montomoli, E.
AU - Lupulescu, E.
AU - Lazar, M.
AU - Cherciu, C. M.
AU - Ranghiasci, Alessia
PY - 2017/7/27
Y1 - 2017/7/27
N2 - We conducted a multicentre test-negative case–control study in 27 hospitals of 11 European countries to measure 2015/16 influenza vaccine effectiveness (IVE) against hospitalised influenza A(H1N1)pdm09 and B among people aged ≥ 65 years. Patients swabbed within 7 days after onset of symptoms compatible with severe acute respiratory infection were included. Information on demographics, vaccination and underlying conditions was collected. Using logistic regression, we measured IVE adjusted for potential confounders. We included 355 influenza A(H1N1)pdm09 cases, 110 influenza B cases, and 1,274 controls. Adjusted IVE against influenza A(H1N1)pdm09 was 42% (95% confidence interval (CI): 22 to 57). It was 59% (95% CI: 23 to 78), 48% (95% CI: 5 to 71), 43% (95% CI: 8 to 65) and 39% (95% CI: 7 to 60) in patients with diabetes mellitus, cancer, lung and heart disease, respectively. Adjusted IVE against influenza B was 52% (95% CI: 24 to 70). It was 62% (95% CI: 5 to 85), 60% (95% CI: 18 to 80) and 36% (95% CI: -23 to 67) in patients with diabetes mellitus, lung and heart disease, respectively. 2015/16 IVE estimates against hospitalised influenza in elderly people was moderate against influenza A(H1N1)pdm09 and B, including among those with diabetes mellitus, cancer, lung or heart diseases.
AB - We conducted a multicentre test-negative case–control study in 27 hospitals of 11 European countries to measure 2015/16 influenza vaccine effectiveness (IVE) against hospitalised influenza A(H1N1)pdm09 and B among people aged ≥ 65 years. Patients swabbed within 7 days after onset of symptoms compatible with severe acute respiratory infection were included. Information on demographics, vaccination and underlying conditions was collected. Using logistic regression, we measured IVE adjusted for potential confounders. We included 355 influenza A(H1N1)pdm09 cases, 110 influenza B cases, and 1,274 controls. Adjusted IVE against influenza A(H1N1)pdm09 was 42% (95% confidence interval (CI): 22 to 57). It was 59% (95% CI: 23 to 78), 48% (95% CI: 5 to 71), 43% (95% CI: 8 to 65) and 39% (95% CI: 7 to 60) in patients with diabetes mellitus, cancer, lung and heart disease, respectively. Adjusted IVE against influenza B was 52% (95% CI: 24 to 70). It was 62% (95% CI: 5 to 85), 60% (95% CI: 18 to 80) and 36% (95% CI: -23 to 67) in patients with diabetes mellitus, lung and heart disease, respectively. 2015/16 IVE estimates against hospitalised influenza in elderly people was moderate against influenza A(H1N1)pdm09 and B, including among those with diabetes mellitus, cancer, lung or heart diseases.
UR - http://www.scopus.com/inward/record.url?scp=85027014121&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85027014121&partnerID=8YFLogxK
U2 - 10.2807/1560-7917.ES.2017.22.30.30580
DO - 10.2807/1560-7917.ES.2017.22.30.30580
M3 - Article
VL - 22
JO - Eurosurveillance
JF - Eurosurveillance
SN - 1560-7917
IS - 30
ER -